Back to top

Is Geron (GERN) Outperforming Other Medical Stocks This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Geron , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Geron is one of 764 individual stocks in the Medical sector. Collectively, these companies sit at #12 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. GERN is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for GERN's full-year earnings has moved 1,000% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the most recent data, GERN has returned 92.78% so far this year. At the same time, Medical stocks have lost an average of 0.69%. This shows that Geron is outperforming its peers so far this year.

Breaking things down more, GERN is a member of the Medical - Biomedical and Genetics industry, which includes 283 individual companies and currently sits at #146 in the Zacks Industry Rank. This group has lost an average of 6.30% so far this year, so GERN is performing better in this area.

Investors with an interest in Medical stocks should continue to track GERN. The stock will be looking to continue its solid performance.




Normally $25 each - click below to receive one report FREE:



More from Zacks Tale of the Tape

You May Like